Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard Weiner, is to receive the Giants of MS award.
The award ceremony will be held on Thursday (May 30), during the Consortium of Multiple Sclerosis Centers annual meeting in Nashville, Tennessee.
Weiner is being recognized for his outstanding contributions to multiple sclerosis (MS) research, added Tiziana.
As co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital and a founding member of Mass General Brigham's healthcare system, his work has significantly advanced the understanding of MS.
This has led to the development of novel therapeutic approaches, including intranasal foralumab, a fully human anti-CD3 monoclonal antibody, said the company.
“We are thrilled to see Dr Howard Weiner recognized with the ‘Giants of MS’ award for his exceptional achievements in MS research,” said Gabriele Cerrone, chairman, acting CEO, and founder of Tiziana Life Sciences.
“Dr Weiner's relentless pursuit of scientific excellence and commitment to improving patient outcomes exemplifies the values we uphold at Tiziana. His contributions have been instrumental in shaping the landscape of MS treatment and inspiring the next generation of researchers.”
Weiner expressed his gratitude for the award, stating, “I am deeply honored to receive the ‘Giants of MS’ award.
“The research community is collectively striving towards a deeper understanding of MS and developing transformative therapies.
“I am immensely grateful for the support of my colleagues, collaborators, and organizations like Tiziana Life Sciences, whose focus on treating MS and dedication to advancing scientific discovery has been integral to our progress.”
Tiziana’s lead candidate, intranasal foralumab, has shown promise in treating MS.
The treatment has demonstrated the ability to stimulate T regulatory cells, which can improve or stabilize patients' conditions.
Currently, an open-label intermediate-size Expanded Access Program is underway, with a Phase 2a trial planned for a 2025 data readout.